Which drug class is used to inhibit the formation of new blood vessels in tumors?

The use of anti-angiogenic agents is pivotal in the treatment of tumors as these agents specifically target the process of angiogenesis, which is the formation of new blood vessels. Tumors require a blood supply to grow and metastasize, and by inhibiting this process, anti-angiogenic agents effectively starve the tumor of nutrients and oxygen. This class of drugs works by blocking the signals that promote the growth of blood vessels, thereby limiting the tumor's ability to expand and spread.

This mechanism is crucial in oncology as it represents a strategic approach to disrupt the tumor's microenvironment. By focusing on the vascular supply essential for tumor growth rather than targeting the cancer cells directly, anti-angiogenic therapies can be utilized in conjunction with other treatment modalities to enhance overall efficacy and improve patient outcomes. Understanding this class of drugs is fundamental for those studying small animal oncopathology, as it reflects a significant evolution in cancer treatment paradigms.